Robert Drolet
Company: Merck
Job title: Translational Biomarker Program Lead
Seminars:
Developing & Optimizing Synuclein PET Ligands for Imaging of Pathological Proteins in Neurodegenerative Disease 2:30 pm
Screening and discovery of small molecule ligands that bind to aggregated alpha-synuclein Optimization and in vivo imaging of MK-7337 a novel PET tracer candidate Clinical strategy for MK-7337 proof-of-concept studies in Parkinson’s disease patients. Read more
day: Conference Day Two
Roundtable Discussion: Laying the Groundwork for Future Advancements in CSF, Plasma & Image-Based Biomarkers of Neurological Disorders 11:45 am
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. What is needed to develop a PET tracer for alpha synuclein to image Parkinson’s in vivo? How can we better associate changes in brain image observations over time with clinically meaningful outcomes in Alzheimer’s and Parkinson’s?…Read more
day: Conference Day Two